- life sciences/pharma sector
-
3rd Annual Therapeutic Monoclonal Antibody Discovery
Enhancing Efficacious and Potent Antibody Therapeutics From Discovery to the Clinic
Event Date: 8-9 Oct 2009
Location: The Fairmont, Battery Wharf, Boston, MA, USA
- key conference speakers
-
Anne De Groot, MD CEO/Professor and Director, Institute for Immunology and Informatics, Epivax, Inc/University of Rhode Island Nancy Stagliano, PhD CEO, Cytomx Mark R. Alfenito, PhD Executive Vice President, Corporate Development, KaloBios Sean Stevens, PhD Head, Immunology, Regeneron Bruce Keyt, PhD Chief Scientific Officer, Trellis Bio
- key conference topics
-
- Assessing Key Drivers for Future Antibody Therapeutics
- Engineering, Designing and Modifying Antibodies for Increased Therapeutic Efficacy
- Employing Best Practices for Antibody Engineering Through Technology Platforms
- Expanding Clinical Utility and Therapeutic Potential of mAbs
- who should attend the conference
-
marcus evans invites senior level executives from leading pharmaceutical and biotech industries with responsibilities or involvement in the following areas:
·Antibody Engineering
·Antibody Technology
·Protein Technology
·Protein Engineering
·Biologics, Biotherapeutics
·Pre-clinical R&D
·Drug Discovery
·Immunology
·R&D
·Preclinical Development
- the conference organisers
-
marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.
Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.
- conference speakers
-
Anne De Groot, MD
CEO/Professor and Director, Institute for Immunology and Informatics
Epivax, Inc/University of Rhode Island
Nancy Stagliano, PhD
CEO
Cytomx
Mark R. Alfenito, PhD
Executive Vice President, Corporate Development
KaloBios
Sean Stevens, PhD
Head, Immunology
Regeneron
Bruce Keyt, PhD
Chief Scientific Officer
Trellis Bio
Mohammad Tabrizi, PhD
Vice President, Preclinical Development
Anaptys Bioscience
David J. King, PhD
Vice President, Research
Anaptys Bioscience
John Babcook
Principle Scientist
Amgen, Inc.
Gadi Gazit-Bornstein, PhD
Principle Scientist, Cancer Research
Astrazenca
William Dall'Acqua, PhD
Director, Research and Development
Medimmune
Mitchell Ho, PhD
Head, Antibody Therapy Unit, Laboratory of Molecular Biology
National Institute of Health
Jun Hayashi, PhD
Vice President, Antibody Precision & Co-Founder
A&G Pharmaceutical Inc, Precision Antibody
Phil Hammond
Director of Molecular Biology
Theraclone Sciences
Dikran Aivazian, PhD
Scientist II, Protein Biochemistry
Biogen Idec
Xiaodong Xiao, PhD
Staff Scientist, Nanobiology Program
National Cancer Institute, NIH
Zdenka Jonak, PhD
Director, Oncology
GSK
Toshihiko Takeuchi
Associate Director, Antibody Discovery and Engineering
Xoma
Chengbin Wu, PhD
Associate Research Fellow
Abbott Bioresearch
- general enquiries
-
Marisse N. Downie - Life Sciences
3rd Floor CGI Tower
Warrens, St. Michael
Barbados
Telephone: 246-417-5391
Fax: 888-844-4901
Email: pharma@marcusevansbb.com
- sponsorship opportunities
-
marcus evans Life Sciences
3rd Floor, CGI Tower
Warrens, St. Michael
Barbados BB12001
Telephone: 888-844-4901
Fax: 246-417-5391
Email: pharma@marcusevansbb.com
- conference quote
-
"Heighten Your Biologics Pipeline With Enhanced and Efficacious Antibody Treatments"
Strengthening Antibody Engineering Through New Tools, Technologies and Processes
